News Archive

November 2019

• Press Release Nov 13, 2019

  Novartis announces new strategy to provide innovative medicines to more patients in sub-Saharan Africa

  The strategy is aligned with the Novartis Access Principles, which aim to systematically integrate access strategies in how the company researches, develops and delivers medicines globally A…
• 
  Story Nov 13, 2019 Patient Perspectives

  Visionary: Silke Mader has a vision for the care of premature infants and their parents

  Caring for a baby with retinopathy of prematurity (ROP) has never been easy. But mother and social visionary Silke Mader has made it her life’s work to ensure that parents dealing with ROP and other complications today get more support than she did.

• Press Release Nov 12, 2019

  Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment

  Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting US analysis of long-term financial impact when…
• Press Release Nov 12, 2019

  New Novartis PREVENT data show Cosentyx® delivers early relief in axial spondyloarthritis

  42.2% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) treated with Cosentyx had improved ASAS40 scores through Week 16; improvements continued through Week 52[1] PREVENT is…
• Press Release Nov 11, 2019

  Novartis data show tropifexor (LJN452) significantly improves several key biomarkers of NASH in patients with moderate to severe fibrosis

  The FLIGHT- FXR phase IIb study showed tropifexor, a highly potent non-bile acid FXR agonist, produces robust and dose-dependent reductions in hepatic fat and alanine aminotransferase compared to…
• Press Release Nov 11, 2019

  Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market

  Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market Planned acquisition reinforces Sandoz…
• 
  Story Nov 08, 2019 From Our Labs

  Turning the power of nuclear technology into a medical force

  Advanced Accelerator Applications is working on marrying targeted drug design with nuclear medicine technology to develop drugs that can recognize and treat diseases.

• 
  Story Nov 08, 2019 Discovery

  Heart failure is a leading cause of hospitalizations, but it doesn’t have to be

  For all too many people living with heart failure, hospitalizations are a recurring part of life, affecting the lives of both patients and their caregivers.

• 
  Story Nov 06, 2019 Access to Healthcare

  Helping people with sickle cell disease, a painful and life-threatening blood disorder

  A collaboration in Ghana aims to expand early diagnosis and treatment of people with this inherited illness.

• Press Release Nov 05, 2019

  Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar Ziextenzo™ (pegfilgrastim-bmez)

  Ziextenzo™ is indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy With approval of Ziextenzo™ , Sandoz is first and only…
• Key Release Nov 01, 2019

  Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis

  Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, while showing numerically higher results versus Humira®*[1] Statistically…
• 
  Story Nov 01, 2019 Discovery

  Can data from a heart disease trial lead to a potential cancer treatment?

  Novartis researchers are learning how a novel approach to immunotherapy could help treat cancer.